 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
1 News |  |
| «12 |
- || Xiyanping / Qingfeng
Clinical, Review, Journal: Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): a scoping review. (Pubmed Central) - Nov 21, 2020
For rehabilitation, Tai Chi and Liuzijue were to be tested for improving patients' lung function. Some potentially promising TCM interventions have been identified and deserve further evaluation to establish their evidence base, particularly on populations outside of China.
- || Xiyanping / Qingfeng
Clinical, Journal: Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations. (Pubmed Central) - Nov 11, 2020
Differences in the type of study, interventions, and registration sources of the studies led to significant differences in certain parameters of the COVID-19 clinical trials. The statistics of high-frequency drugs and the progress of vaccine trials may provide an informative reference for the prevention and control of COVID-19.
- || Xiyanping / Qingfeng
Clinical, Journal, Adverse drug reaction: The effect of ribavirin on the severity of adverse reactions of xiyanping injection: A propensity score-matched analysis. (Pubmed Central) - Nov 7, 2020
This reminds us to pay more attention to the safety of elderly medication. Minimizing the herb-drug-interaction effects of XYP and ribavirin is a viable treatment target for healthcare professionals in managing serious ADRs amongst patients receiving XYP injection.
- Xiyanping / Qingfeng
[VIRTUAL] Multi-center clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronary pneumonia (Live room 7 (online task)) - Oct 31, 2020 - Abstract #CTSChina2020CTS-China_1090;
- || Clinical, Journal, Real-World Evidence: Tabu search algorithm analysis on effect of Xingnaojing Injection in treatment of craniocerebral injury and complications in real world (Pubmed Central) - Sep 20, 2020
For those with shock, Hydroxyethyl Starch+Dopamine Hydrochloride/Dobutamine Hydrochloride+Sodium Bicarbonate should be recommended...The clinical application should be based on patients' specific conditions, clinical benefits and risks, as well as the incompatibility. On the basis of the findings, further studies can be carried out for prospective clinical efficacy evaluation and safety evaluation for a specific subgroup module.
- || Xiyanping / Qingfeng
Clinical, Journal, Real-World Evidence: Analysis of clinical application characteristics of Xiyanping Injection in 194 873 cases in real world (Pubmed Central) - Sep 20, 2020
To pulmonary heart failure, the treatments were Dobutamine + Heparin. Based on the results of the real world HIS, we could provide clinical application the idea, and a reference for further excavation of the applicable diseases of Xiyanping Injection.
- |||| SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
New P2 trial, BRCA Biomarker, PARP Biomarker, Metastases: A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (clinicaltrials.gov) - Sep 19, 2020
P2, N=78, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||| SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
New P2 trial, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov) - Sep 19, 2020
P2, N=104, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- || Xiyanping / Qingfeng
Review, Journal: Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China. (Pubmed Central) - Aug 28, 2020
This report identifies the top 10 CPMs, which include Huoxiang Zhengqi capsule (HXZQC), Lianhua Qingwen capsule (LHQWC), Jinhua Qinggan granule (JHQGG), Shufeng Jiedu capsule (SFJDC), Tanreqing injection (TRQI), Xiyanping injection (XYPI), Xuebijing injection (XBJI), Shenfu injection (SFI), Shengmai injection (SMI), and Angong Niuhuang pill (AGNHP)...In addition, clinical research results and Chinese treatment data showed that the CPMs had good therapeutic efficacy in the treatment of COVID-19, and adverse reactions were minimal. Knowledge of the characteristics of the top 10 CPMs and precautions that should be taken may help clinicians to rationally improve therapeutic efficacy, and promote the role of Chinese Medicine in the control of the COVID-19 global epidemic.
- |||| SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
New P1/2 trial, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (clinicaltrials.gov) - Jul 26, 2020
P1/2, N=90, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- | Xiyanping / Qingfeng
Retrospective data, Journal: Network Meta-analysis of effect of traditional Chinese medicine injections in adjuvant treatment of mycoplasma pneumonia in children (Pubmed Central) - Jun 28, 2020
The results show that traditional Chinese medicine injection has a significant clinical efficacy in the adjuvant treatment of various symptoms of mycoplasma pneumoniae pneumonia in children. Due to the small sample size, more studies are required to verify the strength of evidence.
- || Xiyanping / Jiangxi Qingfeng Pharma
Trial initiation date: Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (clinicaltrials.gov) - May 20, 2020
P=N/A, N=426, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Due to the small sample size, more studies are required to verify the strength of evidence. Initiation date: Feb 2020 --> May 2020
- || Xiyanping / Jiangxi Qingfeng Pharma
Trial initiation date: Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia (clinicaltrials.gov) - May 19, 2020
P=N/A, N=450, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Initiation date: Feb 2020 --> May 2020 Initiation date: Mar 2020 --> Jun 2020
- || Xiyanping / Qingfeng
Clinical, Journal: Expert consensus statement on Xiyanping Injection for respiratory system infectious diseases in clinical practice(adults) (Pubmed Central) - May 6, 2020
The consensus recommended the indication,timing of intervention,usage,dosage,course of treatment,combined medication of Xiyanping Injection used for adults,and introduced the safety and precautions of its clinical application. It is suitable for guiding clinical medical workers to rationally use Xiyanping Injection in the treatment of adult's respiratory infectious diseases.
- || Xiyanping / Qingfeng
Clinical, Journal: Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019 (Pubmed Central) - Apr 18, 2020
The experimental interventions included Chinese patent medicine(Lianhua Qingwen Capsules/Granules, Huoxiang Zhengqi Dropping Pills/Oral Liquid, Babao Dan, Gubiao Jiedu Ling, Jinhao Jiere Granules, Compound Yu-xingcao Mixture, Jinye Baidu Granules, Shufeng Jiedu Capsuless, Shuanghuanglian Oral Liquid, Tanreqing Injection, Xuebijing Injection, Reduning Injection, Xiyanping Injection), Chinese medicinal decoction and taichi...There was a quick response of clinical research on the prevention and treatment of COVID-19 with TCM, with the current registered protocols covers the whole process of disease prevention, treatment and rehabilitation. However, issues need to be concerned, including unclear definition of patient's condition, unclear research objectives, unclear intervention process and inappropriate outcomes, etc. In addition, researchers should consider the actual difficulties and workload of doctors in epidemic response environment, and make effort to optimize the process and improve the operability of research protocols under the principle of medical ethics.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
New trial: Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia (clinicaltrials.gov) - Mar 5, 2020
P=N/A, N=450, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
New trial: Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) (clinicaltrials.gov) - Mar 4, 2020
P=N/A, N=80, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- SC10914 / Qingfeng, Shanghai De Novo Pharmatech
[VIRTUAL] Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors. (Poster Board 218) - Feb 27, 2020 - Abstract #ASCO2020ASCO_611;
P1
The main toxicity was blood-related adverse reactions. SC10914 was effective in gBRCAm ovarian cancer patients.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
New trial, Combination therapy: Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia (clinicaltrials.gov) - Feb 19, 2020
P=N/A, N=348, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||||| Xiyanping / Jiangxi Qingfeng Pharma
Clinical data, New trial, Real-world evidence, Real-world: Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children (clinicaltrials.gov) - Nov 14, 2019
P, N=9207, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
New trial: Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms (clinicaltrials.gov) - May 13, 2019
P=N/A, N=72, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech
New P1 trial, BRCA Biomarker, PARP Biomarker, Metastases: A Study of SC10914 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 29, 2017
P1, N=72, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- || Xiyanping / Jiangxi Qingfeng Pharma
Trial primary completion date: An Add-on Study to Evaluate the Efficacy and Safety of Xiyanping Injection in Pediatric Bronchitis Patients. (clinicaltrials.gov) - Dec 6, 2017
P4, N=240, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
SC10914 was effective in gBRCAm ovarian cancer patients. Trial primary completion date: Aug 2017 --> Apr 2020
- ||||| Xiyanping / Jiangxi Qingfeng Pharma
New P4 trial: Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis (clinicaltrials.gov) - May 1, 2017
P4, N=144, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||||| Xiyanping / Jiangxi Qingfeng Pharma
New P4 trial: A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis (clinicaltrials.gov) - Apr 28, 2017
P4, N=240, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||||| Xiyanping / Jiangxi Qingfeng Pharma
New P4 trial: Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis (clinicaltrials.gov) - Apr 28, 2017
P4, N=144, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||||| Xiyanping / Jiangxi Qingfeng Pharma
New P4 trial: An Add-on Study to Evaluate the Efficacy and Safety of Xiyanping Injection in Pediatric Bronchitis Patients. (clinicaltrials.gov) - Oct 19, 2016
P4, N=240, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| erythromycin / Generic mfg.
Clinical: Effectiveness Study of Integrative Treatment for Pediatric Community Acquired Pneumonia (clinicaltrials.gov) - Feb 13, 2015
P=N/A, N=1500, Recruiting, Sponsor: Liaoning University of Traditional Chinese Medicine
- | capecitabine / Generic mfg.
New P2 trial, Metastases: AGCRC-013: Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer (clinicaltrials.gov) - Nov 21, 2013
P2, N=308, Not yet recruiting, Sponsor: Gu Yanhong
- Xiyanping / Jiangxi Qingfeng Pharma
Clinical: A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=20000, Active, not recruiting, Sponsor: China Academy of Chinese Medical Sciences
- ||| Xiyanping / Jiangxi Qingfeng Pharma
Clinical: Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease (clinicaltrials.gov) - Mar 10, 2012
P=N/A, N=230, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.